Targets › MMP9
2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 1; Immunology, Other, Neurology; next expected readout Dec 2027.
Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption (By similarity). (UniProt, P14780)
Open in Phaseline: the race on MMP9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Southern California | Minocycline Bacterial 70S ribosome inhibitor | MMP9 | Phase 2 | Aneurysm, Ruptured | Dec 2027 |
| Ashibio | Andecaliximab Matrix metalloproteinase 9 inhibitor | MMP9 | Phase 2 | Fibrodysplasia Ossificans Progressiva; Heterotopic Ossification (HO) | Dec 2028 |
Fibrodysplasia Ossificans Progressiva (1) Heterotopic Ossification (HO) (1) Aneurysm, Ruptured (1)
antibody (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.